Peter H. Sayre - Concepedia

Author

Peter H. Sayre

University of California, San Francisco

Also Known As

F. Lublin, P H Sayre, P. H. Sayre, P. Sayre, P.H. Sayre, Peter H Sayre, Peter H. Sayre, Peter Sayre, Rachel Peters

103

Publications

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco Immune Tolerance Network National Institute of Allergy and Infectious Diseases Rho (United States)Harvard University

About

Peter H. Sayre is an author at University of California, San Francisco specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	2.7K
2	Natural Sciences	5	5	365
3	Health Sciences	3	3	36
4	Education	1	1	278
5	Public Health	1	1	80

Peter H. Sayre

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy George Du Toit, Graham Roberts, Peter H. Sayre, New England Journal of Medicine	2015	2.1K
Type 1 diabetes immunotherapy using polyclonal regulatory T cells Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Science Translational Medicine Translational MedicineDiabetes ManagementAutoimmune DiseaseT-regulatory CellDiabetes	2015	993
Effect of Avoidance on Peanut Allergy after Early Peanut Consumption George Du Toit, Peter H. Sayre, Graham Roberts, New England Journal of Medicine	2016	403
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Diabetes	2013	396
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Blood	2020	307
Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study George Du Toit, Graham Roberts, Peter H. Sayre, Journal of Allergy and Clinical Immunology NutritionFood AllergyAllergyAllergy MedicineScreening Study	2012	278
Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression Tatsuo Kawai, David H. Sachs, Ben Sprangers, American Journal of Transplantation	2014	274
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years Kevan C. Herold, Stephen E. Gitelman, Carla J. Greenbaum, Clinical Immunology Type 1Translational MedicineInsulin ProductionDiabetes ManagementAutoimmune Disease	2009	214
ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis Chuan-Hsiung Chang, Gary K. Scott, Wen-Lin Kuo, Oncogene Tumor BiologyBreast OncologyMedicineBreast CancerTumor Suppressor	1997	182
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) Richard A. Nash, George J. Hutton, Michael K. Racke, JAMA Neurology	2014	178

Page 1